Status:
COMPLETED
Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane
Lead Sponsor:
Samsung Medical Center
Conditions:
Preterm Premature Rupture of Membrane
Eligibility:
FEMALE
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the neonatal outcome and infant neurologic outcome whose mother were treated with cefazolin plus clarithromycin for one week or until delivery after preterm pre...
Eligibility Criteria
Inclusion
- preterm premature rupture of membrane(PPROM), PA 22+0\~34+0wks
- ROM \<72 hrs before randomization
- cervical dilatation \<3cm
- uterine contraction less than 4 times per 1 hr
Exclusion
- Major fetal malformation
- Rupture of the membrane \>72hrs before randomization
- Vaginal bleeding
- IIOC (incompetent internal os of cervix)
- Placenta previa
- Gestational diabetes or overt diabetes
- Hypertensive disorders in pregnancy
- Liver cirrhosis
- Acute renal failure
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
151 Patients enrolled
Trial Details
Trial ID
NCT01503606
Start Date
October 1 2011
End Date
December 1 2021
Last Update
April 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical center, Sungkyunkwan University School of Medicine
Seoul, South Korea, 135-710